The efficacy and safety of intravenous immunoglobulin infusion in 12 h for the initial treatment of Kawasaki disease

• প্রধান লেখক: Satoshi Asano (লেখক), Naoya Fukushima (লেখক), Kenichiro Yamada (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Elsevier, 2024-09-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Background: Approximately 10-20 % of individuals develop a recrudescent or persistent fever after intravenous immunoglobulin (IVIG) infusion for the initial treatment of Kawasaki disease. The aim of this study was to evaluate the efficacy and safety of the initial IVIG treatment of Kawasaki disease...